Asterias Biotherapeutics Inc

Asterias Biotherapeutics — Investor Presentation (September 2016)

39 slides from Asterias Biotherapeutics's investor presentation, Sep 12, 2016

  1. Slide 1: Clinical-Stage Cell Therapy Programs Addressing Significant Unmet Medical Needs in Neurology and Oncology

    Clinical-Stage Cell Therapy Programs Addressing Significant Unmet Medical Needs in Neurology and Oncology Asterias Biotherapeutics NYSE MKT: ASTSeptember 2016 14219863Text 04698Text 230237246Text

  2. Slide 2: Forward-Looking Statements

    Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Asterias, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute

  3. Slide 3: Strong Leadership Team with Proven Track Record

    Strong Leadership Team with Proven Track Record Name Experience Steve CarttPresident and CEO Former COO of Questcor PharmaceuticalsLed Questcor’s 2007-2014 commercial strategy, turnaround and multiple expansionsGrew company revenue from $10 million to $1 billionOver 30 years of experience in pharma

  4. Slide 4: Key Highlights

    Key Highlights AST-OPC1 (Pluripotent stem cell platform)Ongoing Phase 1/2a trial in spinal cord injury (SCI); supported by $14.3m grant from CIRMPositive safety profile to-date in two safety cohorts (thoracic SCI trial and cervical SCI trial) Early signs of possible efficacy - one motor level improv

  5. Slide 5: Development Pipeline

    PROGRAM PRECLIN PHASE 1 PHASE 2 PHASE 3 STATUS AST-OPC1*Spinal Cord Injury (subacute) Ph 1/2a ongoing AST-VAC1**Leukemia (AML) Autologous Process development & enhancement in progress AST-VAC2**Lung Cancer Allogeneic Ph 1/2a planning for start Q1 2017 * Potential for application in advanced MS, stro

  6. Slide 6: AST-OPC1

    Pluripotent stem cell platformSignificant grant funding from California Institute of Regenerative Medicine (CIRM)Phase 1/2a clinical trial in spinal cord injury in progress AST-OPC1 14219863Text 04698Text 230237246Text

  7. Slide 7: Spinal Cord Injury: High Unmet Medical Need, Substantial Commercial Opportunity

    Spinal Cord Injury: High Unmet Medical Need, Substantial Commercial Opportunity Spinal cord injury (SCI) affects 17,000 patients per year in U.S.(1)Primarily affects young/healthy males in their 20s and 30s at time of injuryCan be devastating to quality of life and ability to engage in activities of

  8. Slide 8: AST-OPC1: >4,000 patients addressable with target initial SCI label

    AST-OPC1: >4,000 patients addressable with target initial SCI label, plus 5,000 additional patients through SCI label expansion 17,000 new SCI cases in the US annually(1) >4,000 under first label C4-C7 ASIA A/B/C 2016 NSCIC SCI Facts and Figures at a GlanceEstimates by indication calculated based on

  9. Slide 9: AST-OPC1 Addresses the Complex Pathology of SCI

    AST-OPC1 is a cellular therapy utilizing oligodendrocyte progenitor cells (OPCs) AST-OPC1 is made from a well-established , pluripotent embryonic stem cell line originally created in the 1990s; can serve entire OPC1 product lifecycleImportantly, no fetal tissue or adult cells are usedOPCs, which fun

  10. Slide 10: AST-OPC1 Supported by Extensive Pre-Clinical Evaluation

    AST-OPC1 Supported by Extensive Pre-Clinical Evaluation 14219863Text 04698Text 230237246Text Activity Induces persistent myelinationSecretes neurotrophic factorsInduces vascularizationReduces parenchymal cavitation Biodistribution Migrates up 5cm in spinal cordNo distribution outside central nervous

  11. Slide 11: AST-OPC1 SCiSTAR Trial in Complete Cervical Spinal Cord Injury

    AST-OPC1 SCiSTAR Trial in Complete Cervical Spinal Cord Injury (SCI) 14219863Text 04698Text 230237246Text 2016 2017 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 6m Efficacy DMC Cohort 2 – 10M5 subjects AIS-ACohorts AIS-BCohorts Cohort 3 – 20M5 subjects C2 -6m efficacy C2 - 12m efficacy 10M5-8 subjects 20M5-8 subjects Ob

  12. Slide 12: Completed Phase in Thoracic SCI: Million Cell Dose

    Completed Phase 1 in Thoracic SCI: 2 Million Cell DoseWell Tolerated, Signs of Clinical Activity on MRI A Phase 1 Trial was conducted in five patients with neurologically complete, thoracic SCITrial was not expected to demonstrate efficacy – low dose of 2 million AST-OPC1 cells was administered(5-10

  13. Slide 13: Ongoing Phase 1/2a Study in Cervical SCI: Million Cell Dose

    Ongoing Phase 1/2a Study in Cervical SCI: 2 Million Cell DoseWell Tolerated, Measurable Signs of Clinical Activity Very low dose (2 million cells), safety-only portion of the ongoing trial was conducted in three patients with neurologically complete, cervical SCINo safety issues observed, confirming

  14. Slide 14: Interim Efficacy Data to be Presented September 14 at ISCoS Conference

    Ongoing Phase 1/2a Study in Cervical SCI: 10 Million Cell DoseInterim Efficacy Data to be Presented September 14 at ISCoS Conference Lowest of two efficacy doses (10 and 20 million cells) to be tested in complete cervical SCI patientsNo safety issues observed to dateInterim AST-OPC1 efficacy data to

  15. Slide 15: ISNCSCI Scale is a Key Measurement Tool for SCI Recovery

    Widely adopted tool for clinical assessment of neurological impairment after SCIMeasures changes in motor function, motor score, other key metricsTwo motor level improvement in the upper extremities is believed by experts to represent a clinically meaningful improvement in functioning, leading to si

  16. Slide 16: ISNCSCI Exam ISCoS ISNCSCI Algorithm

    ISNCSCI Exam ISCoS ISNCSCI Algorithm

  17. Slide 17: AST-OPC1 Therapy is Designed to Increase Patient Motor Function and Improve Quality of Life

    AST-OPC1 Therapy is Designed to Increase Patient Motor Function and Improve Quality of Life & Ability to Live Independently Capability C1-C3 C4 C5 C6 C7-C8 Bowel Bladder Bed Mobility Transfers Pressure Relief Eating Dressing Grooming Bathing Wheelchair Car Transport Daily Home Care 24 hr Attendant 1

  18. Slide 18: Patient Recently Treated in SCiSTAR Study at USC

    Patient Recently Treated in SCiSTAR Study at USC

  19. Slide 19: Projected AST-OPC1 Data Milestones

    Milestone Est. Date Interim efficacy data from AIS-A Cohort 2 (10M cells) September 14, 2016 6 month data from AIS-A Cohort 2 (10M cells) January 2017 12 month data from AIS-A Cohort 2 (10M cells) July 2017 6 month data from AIS-B Cohort 1 (10M cells) Q3 2017 6 month data from AIS-A Cohort 3 (20M ce

  20. Slide 20: AST-VAC1

    Patient-specific (autologous)Acute Myelogenous Leukemia (AML)Process development/enhancement in progress AST-VAC1 14219863Text 04698Text 230237246Text

  21. Slide 21: AST-VAC1 Targets AML Need in Older and High-Risk Patients

    ~19,000 new AML cases diagnosed and ~10,500 deaths from AML in U.S. annually(1)AML incidence increases markedly after 60, and older patients do not tolerate AML therapies wellAverage age of an AML patient is 67Patients over 60 often have trouble tolerating intensive treatmentMany are poor candidates

  22. Slide 22: AST-VAC1 Has Potential to Safely Maintain AML Remission

    AST-VAC1 Has Potential to Safely Maintain AML Remission AML Two-Step Treatment Paradigm: Induction and Maintenance of Remission Step 1: InductionChemotherapy to get patients into complete remissionMost new AML therapies in development are targeting Induction of Remission Step 2: Consolidation/Mainte

  23. Slide 23: Proof of Concept in Phase 2 Trial

    57% 10-20% >60 years oldN = 7 20-40% 58% All patientsN = 19 Relapse Free Survival at 52 Months(% of patients) Historical(2) AST-VAC1(1) VAC1 Phase 2 results, presented at ASCO, May 2015; manuscript submittedMayer NEJM 1994; Rollig, J Clin Onc 2011ITP is commonly observed in AML patients and may not

  24. Slide 24: Path Forward for AST-VAC1 Development

    Path Forward for AST-VAC1 Development Critical path item is development/enhancement of the AST-VAC1 production process; effort underway, projected completion mid-2017 reduce cycle time, COGSPositive meeting with FDA based on open-label phase 2 efficacy signal and favorable safety profileFDA would su

  25. Slide 25: AST-VAC2

    Non-patient specific (allogeneic), “ready-for-use”Non-small cell lung cancer (NSCLC)Development partnership with Cancer Research UKPlanning Phase 1/2a clinical trial to start Q1 2017 AST-VAC2 14219863Text 04698Text 230237246Text

  26. Slide 26: AST-VAC2 Targets an Unmet Need in NSCLC

    AST-VAC2 Targets an Unmet Need in NSCLC, a Very Large Population of Cancer Patients with High Mortality Rate Not Staged3% Lung cancer is the most common type of cancer(1)Estimated 1.8M new cases and 1.6M lung cancer deaths worldwide in 2012~220,000 new cases and ~160,000 deaths annually in the U.S.8

  27. Slide 27: AST-VAC2 is Allogeneic, 'Ready for Use,' Non-Patient Specific

    AST-VAC2 is Allogeneic, ‘Ready for Use,’ Non-Patient Specific AST-VAC2 cells are mature allogeneic dendritic cells that have been transfected with hTERT and LAMP(4,5), similarly to AST-VAC1Not patient-specific: no need to produce individualized vaccines for each patientAST-VAC2 is ready to use on de

  28. Slide 28: Phase 1/2a Trial to be Funded Through CRUK Partnership

    Anticipate MHRA clearance for Phase 1/2a NSCLC trial early Q1 2017Clinical trial sites open for enrollment Q1 2017Partnership with Cancer Research UK (CRUK) funds full cost of GMP manufacturing, regulatory filing, and Phase 1/2a trialCRUK partnership saves Asterias an estimated ~$30MFollowing a succ

  29. Slide 29: Key Takeaways

    Key Takeaways AST-OPC1 (Pluripotent stem cell platform)Ongoing SCiSTAR Phase 1/2a trial in spinal cord injury (SCI)September 14 interim efficacy data release for first efficacy cohort of 10m cells dosed; 6 month readout January 2017, additional readouts 2017-2018AST-VAC1 (Cancer Immunotherapy platfo

  30. Slide 30: Appendix

    APPENDIX 14219863Text 04698Text 230237246Text

  31. Slide 31: Corporate History

    Asterias: a publicly traded, independently operated company that is presently <48% owned by Biotime (BTX) September 2012 – BioTime (BTX) creates Asterias to acquire assets in the field of regenerative medicineOctober 2013 – Asterias acquires cell therapy assets from Geron, including INDs for the cli

  32. Slide 32: AST-OPC1 Accomplishes Three Major Physiologically Relevant Functional Activities

    AST-OPC1 Accomplishes Three Major Physiologically Relevant Functional Activities 14219863Text 04698Text 230237246Text shiverer mouse shi mouse + AST-OPC1 Wraps host neurons and forms compact myelin sheaths AST-OPC1 CM Control Media TubIII Produces neurotrophic factors and stimulates neurite outgrow

  33. Slide 33: AST-OPC1: Demonstrated Activity in Preclinical SCI Model

    AST-OPC1: Demonstrated Activity in Preclinical SCI Model hNucEC 1 mm 100 µm AST-OPC1 in SCI lesion, significantly reduced cavity formation Robust AST-OPC1 survival (brown) Myelinated fibers (blue) 9 Months Vehicle hNucEC 1 mm 100 µm Cavity forms in untreated SCI lesion Myelinated axons do not extend

  34. Slide 34: AST-OPC1: Spinal Cord Anatomy and Levels of Injury

    AST-OPC1: Spinal Cord Anatomy and Levels of Injury 14219863Text 04698Text 230237246Text Spinal cord injuries typically result in complete or partial loss of movement and sensation below the level of the injuryPatients with cervical injuries typically lose function in all four limbs (quadraplegia/tet

  35. Slide 35: Clinical-Stage Regenerative Platform Technologies

    Pluripotent Stem Cells Scalable source from well-established stem cell lines to produce desired cell types resulting in “off the shelf” therapeutics to restore functional tissueAST-OPC1: Neural cell type (oligodendrocyte progenitor cells, OPCs); multiple MOAs to restore lost function in neurodegener

  36. Slide 36: AST-VAC1: Significant Unmet Need to Extend Remission in AML

    Rollig J Clin Onc 2011 Decision Resources Relapse-Free Survival (RFS) in AML Patients >60 years of Age Treated with Standard of Care(1) Only 10-20% RFS at 4 years AST-VAC1: Significant Unmet Need to Extend Remission in AML “The incidence of AML continues to increase with the aging population. The su

  37. Slide 37: AST-VAC1: Activating a Patient's Immune System

    AST-VAC1: Activating a Patient’s Immune System Dendritic Cells: Potent Antigen Presenting Cells AST-VAC1 is an autologous cell-based immunotherapy that enables a patient’s own dendritic cells (DCs) to stimulate an immune response to telomerase, a universal cancer antigenIsolated monocytes are stimul

  38. Slide 38: VAC Technology is Designed to Overcome Limitations of First-Generation Dendritic Cell Therapies

    VAC Technology is Designed to Overcome Limitations of First-Generation Dendritic Cell Therapies Six distinct design characteristics differentiate Asterias’ VAC products from first-generation DC therapies LAMP sequenceEnhance immune response to telomerase Cryopreserved productSimplify supply chain Ma

  39. Slide 39: AST-VAC1: Safety Demonstrated in Phase 1 and Phase 2 Trials

    AST-VAC1: Safety Demonstrated in Phase 1 and Phase 2 Trials AST-VAC1 demonstrated favorable safety profile in two clinical trialsOnly 1 out of 41 patients exhibited a possibly related SAE Patients Receiving VAC1 Safety Results Phase 1 TrialSu Z, Journal of Immunology 2005 20 patients with metastatic

Asterias Biotherapeutics — Investor Presentation (September 2016) on 6ix